[go: up one dir, main page]

WO2003045321A3 - MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE - Google Patents

MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE Download PDF

Info

Publication number
WO2003045321A3
WO2003045321A3 PCT/US2002/037777 US0237777W WO03045321A3 WO 2003045321 A3 WO2003045321 A3 WO 2003045321A3 US 0237777 W US0237777 W US 0237777W WO 03045321 A3 WO03045321 A3 WO 03045321A3
Authority
WO
WIPO (PCT)
Prior art keywords
branching morphogenesis
methods
mbms
modifiers
mbm
Prior art date
Application number
PCT/US2002/037777
Other languages
French (fr)
Other versions
WO2003045321A2 (en
Inventor
Felix D Karim
Linda Nolan Keyes
Gregory D Plowman
Original Assignee
Exelixis Inc
Felix D Karim
Linda Nolan Keyes
Gregory D Plowman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Felix D Karim, Linda Nolan Keyes, Gregory D Plowman filed Critical Exelixis Inc
Priority to AU2002359474A priority Critical patent/AU2002359474A1/en
Publication of WO2003045321A2 publication Critical patent/WO2003045321A2/en
Publication of WO2003045321A3 publication Critical patent/WO2003045321A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/70—Invertebrates
    • A01K2227/706—Insects, e.g. Drosophila melanogaster, medfly
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Human MBM genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morphogenesis, comprising screening for agents that modulate the activity of MBM are provided.
PCT/US2002/037777 2001-11-26 2002-11-25 MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE WO2003045321A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002359474A AU2002359474A1 (en) 2001-11-26 2002-11-25 MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US33337101P 2001-11-26 2001-11-26
US33337901P 2001-11-26 2001-11-26
US33337401P 2001-11-26 2001-11-26
US33334301P 2001-11-26 2001-11-26
US60/333,379 2001-11-26
US60/333,343 2001-11-26
US60/333,371 2001-11-26
US60/333,374 2001-11-26
US33451501P 2001-11-30 2001-11-30
US33454501P 2001-11-30 2001-11-30
US33454001P 2001-11-30 2001-11-30
US33454201P 2001-11-30 2001-11-30
US33453701P 2001-11-30 2001-11-30
US60/334,515 2001-11-30
US60/334,537 2001-11-30
US60/334,540 2001-11-30
US60/334,545 2001-11-30
US60/334,542 2001-11-30
US33827601P 2001-12-05 2001-12-05
US60/338,276 2001-12-05

Publications (2)

Publication Number Publication Date
WO2003045321A2 WO2003045321A2 (en) 2003-06-05
WO2003045321A3 true WO2003045321A3 (en) 2004-02-26

Family

ID=27581241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/037777 WO2003045321A2 (en) 2001-11-26 2002-11-25 MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE

Country Status (2)

Country Link
AU (1) AU2002359474A1 (en)
WO (1) WO2003045321A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004253881A1 (en) 2003-06-19 2005-01-13 Exelixis, Inc. NADKs as modifiers of branching morphogenesis and methods of use
WO2005072470A2 (en) * 2004-01-28 2005-08-11 Exelixis, Inc Mbms as modifiers of branching morphogenesis and methods of use
GB0404929D0 (en) * 2004-03-04 2004-04-07 Inpharmatica Ltd Protein
JP4191189B2 (en) * 2005-12-08 2008-12-03 康生 梅津 Peptides with cancer-related gene activation ability
US9277737B2 (en) 2006-09-21 2016-03-08 Probiodrug Ag Mouse models carrying a knock-out mutation of the QPCTL-gene
US8889709B2 (en) 2006-09-21 2014-11-18 Probiodrug Ag Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions
WO2008034891A2 (en) 2006-09-21 2008-03-27 Probiodrug Ag Novel genes related to glutaminyl cyclase
GB201011819D0 (en) * 2010-07-14 2010-09-01 King S College London Neurodegenerative disorders
WO2012028706A1 (en) * 2010-09-02 2012-03-08 Probiodrug Ag IN VIVO SCREENING MODELS FOR TREATMENT OF isoQC-RELATED DISORDERS
US9447193B2 (en) * 2013-03-24 2016-09-20 Development Center For Biotechnology Methods for suppressing cancer by inhibition of TMCC3

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013787A (en) * 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense modulation of Smad4 expression
US6420526B1 (en) * 1997-03-07 2002-07-16 Human Genome Sciences, Inc. 186 human secreted proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420526B1 (en) * 1997-03-07 2002-07-16 Human Genome Sciences, Inc. 186 human secreted proteins
US6013787A (en) * 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense modulation of Smad4 expression

Also Published As

Publication number Publication date
AU2002359474A1 (en) 2003-06-10
AU2002359474A8 (en) 2003-06-10
WO2003045321A2 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
WO2002099058A3 (en) KCNMAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2002099074A3 (en) Slc7s as modifiers of the p53 pathway and methods of use
WO2003014301A3 (en) Hprp4s as modifiers of the p53 pathway and methods of use
WO2003045321A3 (en) MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
WO2004038371A3 (en) Ccr8 as modifier of branching morphogenesis and methods of use
WO2003051905A3 (en) Taojiks as modifiers of the beta-catenin pathway and methods of use
WO2002099043A8 (en) P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2004037990A3 (en) MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
WO2004013309A3 (en) PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
WO2005052132A3 (en) Mbms as modifiers of branching morphogenesis and methods of use
WO2003035831A3 (en) Lrrcaps as modifiers of the p53 pathway and methods of use
WO2004024891A3 (en) MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
WO2003045314A3 (en) Mhyps as modifiers of branching morphogenesis and methods of use
WO2005072470A3 (en) Mbms as modifiers of branching morphogenesis and methods of use
WO2004005484A3 (en) Snrks as modifiers of chk and branching morphogenesis and methods of use
WO2004014301A3 (en) PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE
WO2004113503A3 (en) Mbms as modifiers of branching morphogenesis and methods of use
WO2005017123A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2004048538A3 (en) Csnks as modifiers of the rac pathway and methods of use
WO2004048541A3 (en) Cct6s as modifiers of the rb pathway and methods of use
WO2003074673A3 (en) Lgals as modifiers of the chk pathway and methods of use
WO2003074677A3 (en) MCHKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE
WO2003052068A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2005001026A3 (en) Adks as modifiers of the pten pathway and methods of use
WO2003052070A3 (en) Vps41s as modifiers of cell death and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP